Teza Capital Management’s Haemonetics HAE Stock Holding History

Teza Capital Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,578	Closed	-$645K	–	668
2023 Q2	$645K	Buy	+7,578	New	+$641K	0.1%	257
2022 Q4	–	Sell	-2,850	Closed	-$211K	–	639
2022 Q3	$211K	Buy	+2,850	New	+$205K	0.04%	490
2020 Q3	–	Sell	-4,328	Closed	-$388K	–	477
2020 Q2	$388K	Buy	+4,328	New	+$437K	0.09%	336
2020 Q1	–	Sell	-3,042	Closed	-$350K	–	289
2019 Q4	$350K	Buy	+3,042	New	+$368K	0.1%	380
2018 Q3	–	Sell	-3,572	Closed	-$320K	–	452
2018 Q2	$320K	Buy	+3,572	New	+$302K	0.05%	414

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Teza Capital Management's HAE Position: Q3 2023 in Review

Teza Capital Management sold out of Haemonetics (HAE) in Q3 2023, closing a stake of 7,578 shares — an estimated $645K sold.

Teza Capital Management first reported a position in HAE in Q2 2018 and held it in 5 quarters. The position peaked at $645K in Q2 2023. 296 funds tracked by Wall St. Rank hold HAE as of Q3 2023.

Teza Capital Management reported no remaining Haemonetics position as of Q3 2023 after selling out during the quarter.
Teza Capital Management sold 7,578 Haemonetics shares in Q3 2023, an estimated $645K.
Teza Capital Management first reported a position in Haemonetics in Q2 2018 and held it in 5 quarters.
Teza Capital Management's Haemonetics position peaked at $645K in Q2 2023.
296 funds tracked by Wall St. Rank held Haemonetics as of Q3 2023.

Based on Teza Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.